E. Freeman

Lenvatinib for the treatment of hepatocellular carcinoma—a real-world multicenter Australian cohort study

P. Gow, S. Bell, G. McCaughan, 2022, Hepatology International.

Epidemiology and outcomes of primary sclerosing cholangitis: an Australian multicentre retrospective cohort study

P. Gow, K. Lynch, J. Lubel, 2022, Hepatology International.

Lenvatinib for the treatment of hepatocellular carcinoma—a real-world multicenter Australian cohort study

P. Gow, S. Bell, G. McCaughan, 2022, Hepatology International.

Long‐term outcomes of primary sclerosing cholangitis: an Australian non‐transplant tertiary hospital perspective

W. Kemp, S. Roberts, A. Majeed, 2019, Internal medicine journal.

Autoimmune hepatitis developing after the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine

S. Roberts, W. Kemp, E. Freeman, 2021, Journal of Hepatology.

Autoimmune hepatitis developing after the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine

S. Roberts, W. Kemp, E. Freeman, 2021, Journal of Hepatology.

Irreversible electroporation versus radiofrequency ablation for hepatocellular carcinoma: a single centre propensity-matched comparison

H. Kavnoudias, W. Cheung, S. Roberts, 2021, Scandinavian journal of gastroenterology.

Irreversible Electroporation For Hepatocellular Carcinoma: Longer-Term Outcomes At A Single Centre

H. Kavnoudias, W. Cheung, S. Roberts, 2020, CardioVascular and Interventional Radiology.